Profusa was awarded a $7.5 million grant from the Defense Advanced Research Projects Agency (DARPA) and the U.S. Army Research Office to develop implantable biosensors for the simultaneous, continuous ...

Profusa, a company that is developing connected tissue-implanted biosensors, has raised just over $45 million in Series C funding. Participants in the round included new investors VMS Investment Group ...

The Defense Advanced Research Projects Agency announced a project with the U.S. Army Research Office to develop tissue-integrated biosensor technology. Profusa, a San Francisco company, was awarded a ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. The ...

(RTTNews) - Profusa, Inc. (PFSA) has taken a significant step toward commercializing its biosensor technology with the launch of its Lumee tissue-oxygen healthcare and research offerings, a move that ...

Profusa scored a CE mark for its injectable biosensor system that continuously monitors dissolved oxygen in tissues. The company will initially market the platform for tissue oxygen monitoring in the ...

SAN FRANCISCO, Oct. 15, 2018 /PRNewswire/ -- Profusa, a company dedicated to the development of tissue-integrating biosensors for the continuous monitoring of body chemistries, today announced it has ...

Imagine, throughout your day, you could know exactly what your body chemistry was up to. More specifically, imagine if the information from your body could instantly go to your doctor and he could ...

Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s ...